Ispire Technology Inc. Reports Strong Financial Performance in Q1 2024

Business by 2FIRSTS.ai
Nov.15.2023
Ispire Technology Inc. Reports Strong Financial Performance in Q1 2024
Ispire Technology Inc., a Nasdaq-listed company, announced its financial report for Q1 of FY2024 with revenue growth of 59.1%.

On November 14th, Ispire Technology Inc. (NASDAQ: ISPR), a company listed on the Nasdaq stock exchange, released its financial report for the first quarter of the 2024 fiscal year, which ended on September 30th, 2023.

 

In the first quarter of the fiscal year 2024, the operating revenue reached $42.9 million, a year-on-year increase of 59.1%. Among them, the revenue from tobacco e-cigarette products increased by 34.8% to reach $25.5 million, while revenue from cannabis e-cigarette products increased by 116.8% to reach $17.3 million. The gross profit reached $6.9 million, recording a growth of 43.7%. Meanwhile, the total operating expenses increased from $6 million in the same period of 2023 to $7.8 million, showing a growth of 29.8%.

 

According to reports, Ispire sells its tobacco products under the brand Aspire, primarily through its distribution network worldwide (excluding the United States, the People's Republic of China, and Russia). Ispire's cannabis products are mainly sold to other cannabis vaporizer companies under the original design manufacturer (ODM) model, using the Ispire brand. Currently, Ispire only sells its cannabis e-cigarette hardware in the United States and has recently launched marketing campaigns in Canada and Europe (primarily the European Union).

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.